Sanofi (SNY) Receives Price Target

Sanofi (SNY) : Average target price received by Sanofi (SNY) is $51 with an expected standard deviation of $7.07. The most aggressive target on the stock is $56, whereas the most downbeat target is $46. 2 financial analysts are currently covering the stock.

Sanofi (SNY) : Zacks Investment Research ranks Sanofi (SNY) as 4, which is a Sell recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 4 research analysts is 2, which indicates as a Buy.


Sanofi (NYSE:SNY): The stock opened at $38.33 on Thursday but the bulls could not build on the opening and the stock topped out at $38.52 for the day. The stock traded down to $38.17 during the day, due to lack of any buying support eventually closed down at $38.41 with a loss of -0.16% for the day. The stock had closed at $38.47 on the previous day. The total traded volume was 2,106,302 shares.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Companys principal activities. Under the Companys Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.